Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588348859> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2588348859 endingPage "vi318" @default.
- W2588348859 startingPage "vi318" @default.
- W2588348859 abstract "Indoleamine 2,3-dioxygenase (IDO) is an intracellular enzyme that mediates the metabolism of the essential amino acid L-tryptophan into immunosuppressive metabolites, such as kynurenine and 3-hydroxyanthranilic acid. IDO is a key factor maintaining immune tolerance, and is overexpressed in several human cancers: prostate, breast, brain, and hematologic malignancies. Mechanisms leading to expression of IDO in human tumors are still unknown. Our study aims to investigate the role of IDO expression in clinical behavior of diffuse large B-cell lymphoma (DLBCL). The case group included 23 patients (6 males, 17 females) with DLBCL (median age: 48.5 years, range: 23-74). The patients were treated with R-CHOP/CHOP, CHOEP, R-DA-EPOCH. Remission was achieved in 52.1% of the cases and in 47.8% disease progression after treatment was continued. The relative mRNA expression levels of IDO were measured in pre-treatment tumour tissue specimens from DLBCL patients using qPCR analysis. The mRNA expression of IDO was found in 11 cases (48%) and further this group was considered as IDO-positive. The presence of IDO expression was significantly associated with advanced stage of disease (p < 0.05), ABC subtype and progression of DLBCL (17.4% vs. 4.3%, p < 0.05). The complete remission rate was significantly increased in IDO-negative group compared to IDO-positive DLBCL (34.7% vs. 21.7%, p < 0.05). ROC analysis revealed that IDO-positive expression in tumor is an important marker associated with reduced progression-free survival (PFS) in DLBCL patients (Se = 72.7%; Sp = 75%; AUC = 0.73). The 4-year PFS rate for IDO-positive DLBCL patients was 50% compared to 73% for IDO-negative DLBCL patients (p = 0.002). Results suggest that IDO expression correlates with the disease progression and impaired clinical outcome in DLBCL patients. The presence of IDO expression in tumour tissue should be considered as an additional unfavorable prognostic risk factor to patients with DLBCL, especially for ABC subtype. It may represent a promising therapeutic target for DLBCL patients with resistance to chemotherapy. Ongoing studies from our group are currently evaluating the impact of immune escape checkpoints on patients' survival." @default.
- W2588348859 created "2017-02-24" @default.
- W2588348859 creator A5002529664 @default.
- W2588348859 creator A5042246214 @default.
- W2588348859 creator A5042598500 @default.
- W2588348859 creator A5043534780 @default.
- W2588348859 creator A5048770576 @default.
- W2588348859 creator A5052049559 @default.
- W2588348859 creator A5056485244 @default.
- W2588348859 creator A5059553886 @default.
- W2588348859 creator A5064272055 @default.
- W2588348859 creator A5076696603 @default.
- W2588348859 creator A5077438816 @default.
- W2588348859 creator A5084918571 @default.
- W2588348859 creator A5087852699 @default.
- W2588348859 date "2016-10-01" @default.
- W2588348859 modified "2023-09-28" @default.
- W2588348859 title "The role of indoleamine 2,3-dioxygenase expression in diffuse large B-cell lymphoma prognosis" @default.
- W2588348859 doi "https://doi.org/10.1093/annonc/mdw375.17" @default.
- W2588348859 hasPublicationYear "2016" @default.
- W2588348859 type Work @default.
- W2588348859 sameAs 2588348859 @default.
- W2588348859 citedByCount "1" @default.
- W2588348859 countsByYear W25883488592020 @default.
- W2588348859 crossrefType "journal-article" @default.
- W2588348859 hasAuthorship W2588348859A5002529664 @default.
- W2588348859 hasAuthorship W2588348859A5042246214 @default.
- W2588348859 hasAuthorship W2588348859A5042598500 @default.
- W2588348859 hasAuthorship W2588348859A5043534780 @default.
- W2588348859 hasAuthorship W2588348859A5048770576 @default.
- W2588348859 hasAuthorship W2588348859A5052049559 @default.
- W2588348859 hasAuthorship W2588348859A5056485244 @default.
- W2588348859 hasAuthorship W2588348859A5059553886 @default.
- W2588348859 hasAuthorship W2588348859A5064272055 @default.
- W2588348859 hasAuthorship W2588348859A5076696603 @default.
- W2588348859 hasAuthorship W2588348859A5077438816 @default.
- W2588348859 hasAuthorship W2588348859A5084918571 @default.
- W2588348859 hasAuthorship W2588348859A5087852699 @default.
- W2588348859 hasBestOaLocation W25883488591 @default.
- W2588348859 hasConcept C126322002 @default.
- W2588348859 hasConcept C143998085 @default.
- W2588348859 hasConcept C2776706248 @default.
- W2588348859 hasConcept C2777503454 @default.
- W2588348859 hasConcept C2778559949 @default.
- W2588348859 hasConcept C2779338263 @default.
- W2588348859 hasConcept C2779725641 @default.
- W2588348859 hasConcept C502942594 @default.
- W2588348859 hasConcept C515207424 @default.
- W2588348859 hasConcept C55493867 @default.
- W2588348859 hasConcept C71924100 @default.
- W2588348859 hasConcept C83478079 @default.
- W2588348859 hasConcept C86803240 @default.
- W2588348859 hasConceptScore W2588348859C126322002 @default.
- W2588348859 hasConceptScore W2588348859C143998085 @default.
- W2588348859 hasConceptScore W2588348859C2776706248 @default.
- W2588348859 hasConceptScore W2588348859C2777503454 @default.
- W2588348859 hasConceptScore W2588348859C2778559949 @default.
- W2588348859 hasConceptScore W2588348859C2779338263 @default.
- W2588348859 hasConceptScore W2588348859C2779725641 @default.
- W2588348859 hasConceptScore W2588348859C502942594 @default.
- W2588348859 hasConceptScore W2588348859C515207424 @default.
- W2588348859 hasConceptScore W2588348859C55493867 @default.
- W2588348859 hasConceptScore W2588348859C71924100 @default.
- W2588348859 hasConceptScore W2588348859C83478079 @default.
- W2588348859 hasConceptScore W2588348859C86803240 @default.
- W2588348859 hasLocation W25883488591 @default.
- W2588348859 hasOpenAccess W2588348859 @default.
- W2588348859 hasPrimaryLocation W25883488591 @default.
- W2588348859 hasRelatedWork W1797732564 @default.
- W2588348859 hasRelatedWork W2090012912 @default.
- W2588348859 hasRelatedWork W2094644987 @default.
- W2588348859 hasRelatedWork W2171137688 @default.
- W2588348859 hasRelatedWork W2334374063 @default.
- W2588348859 hasRelatedWork W2390430401 @default.
- W2588348859 hasRelatedWork W2511204845 @default.
- W2588348859 hasRelatedWork W2977628627 @default.
- W2588348859 hasRelatedWork W3031860663 @default.
- W2588348859 hasRelatedWork W3133915593 @default.
- W2588348859 hasVolume "27" @default.
- W2588348859 isParatext "false" @default.
- W2588348859 isRetracted "false" @default.
- W2588348859 magId "2588348859" @default.
- W2588348859 workType "article" @default.